Outcomes of HCV Therapy in HIV-Coinfected Patients

Aggressively managing hematologic toxicities to optimize adherence with and dosing of HCV therapy results in better treatment outcomes.

Patients coinfected with HIV and hepatitis C virus (HCV) tend to have worse HCV treatment outcomes than monoinfected patients do, and they may also experience more-pronounced side effects from these treatments. Severe neutropenia, anemia, and thrombocytopenia often necessitate dose reduction, drug discontinuation, or use of colony-stimulating factors. To determine whether such treatment interventions affect outcomes of HCV therapy, ACTG investigators analyzed data from an open-label, randomized controlled trial of interferon alfa-2a (IFN) versus pegylated interferon alfa-2a (PEG-IFN), both with ribavirin, in 133 HIV/HCV-coinfected patients.

All the study participants had baseline neutrophil counts >1000 cells/mm³, hemoglobin levels ≥10.5 g/d…

Reviewing Author

Sonia Nagy Chimienti, MD

Outcomes of HCV Therapy in HIV-Coinfected Patients

Topics

Reviewing Author